From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
Covered without a code on the Ontario formulary: ACLIDINIUM BROMIDE, GLYCOPYRRONIUM BROMIDE, UMECLIDINIUM
ACLIDINIUM BROMIDE · General benefit
INDICATIONS AND CLINICAL USE
TUDORZA GENUAIR (aclidinium bromide) is indicated as a long-term maintenance
bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD),
including chronic bronchitis and emphysema.
PM: https://pdf.hres.ca/dpd_pm/00067375.PDF; date not captured; DIN 02409720; fetched 2026-09-10
Product monograph
ACLIDINIUM BROMIDE & FORMOTEROL FUMARATE DIHYDRATE · Limited Use, codes 459
INDICATIONS AND CLINICAL USE
DUAKLIR GENUAIR (aclidinium bromide/formoterol fumarate dihydrate) is a combination
of a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA)
indicated as a long-term maintenance bronchodilator treatment for airflow obstruction in
patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis
and/or emphysema.
PM: https://pdf.hres.ca/dpd_pm/00067361.PDF; date not captured; DIN 02439530; fetched 2026-09-10
Product monograph
FLUTICASONE FUROATE & VILANTEROL · Limited Use, codes 330, 456 (1), Limited Use, codes 330 (1)
INDICATIONS AND CLINICAL USE
COPD
BREO ELLIPTA (fluticasone furoate/vilanterol) 100/25 mcg is a combination of an
inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA),
indicated for the long-term once-daily maintenance treatment of airflow obstruction in
patients with chronic obstructive pulmonary disease (COPD), including chronic
bronchitis and/or emphysema, and to reduce exacerbations of COPD in patients with a
history of exacerbations.
PM: https://pdf.hres.ca/dpd_pm/00049111.PDF; date January 7, 2019; DIN 02408872; fetched 2026-09-10
Product monograph
GLYCOPYRRONIUM BROMIDE · General benefit
1 INDICATIONS
SEEBRI ® BREEZHALER ® (glycopyrronium bromide) is indicated as a long-term once-daily maintenance
bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD), including
chronic bronchitis and emphysema.
PM: https://pdf.hres.ca/dpd_pm/00067963.PDF; date October 16, 2012; DIN 02394936; fetched 2026-09-10
Product monograph
INDACATEROL & GLYCOPYRRONIUM · Limited Use, codes 459
1 INDICATIONS
ULTIBRO BREEZHALER (indacaterol maleate and glycopyrronium bromide) is a combination of a long-
acting beta2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA), indicated for the long-term
once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic
obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and for the
reduction of exacerbations of COPD in patients with a history of exacerbations.
PM: https://pdf.hres.ca/dpd_pm/00072513.PDF; date Dec 23, 2013; DIN 02418282; fetched 2026-09-10
Product monograph
TIOTROPIUM BROMIDE MONOHYDRATE & OLODATEROL HYDROCHLORIDE · Limited Use, codes 459
INDICATIONS AND CLINICAL USE
INSPIOLTO RESPIMAT (tiotropium bromide monohydrate and olodaterol hydrochloride) is a
combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-adrenergic
agonist (LABA) indicated for the long term, once daily maintenance bronchodilator treatment of
airflow obstruction in patients with Chronic Obstructive Pulmonary Disease (COPD), including
chronic bronchitis and emphysema.
PM: https://pdf.hres.ca/dpd_pm/00054220.PDF; date November 14, 2019; DIN 02441888; fetched 2026-09-10
Product monograph
UMECLIDINIUM · General benefit
1 INDICATIONS
INCRUSE ELLIPTA (umeclidinium) is indicated for the long-term once-daily maintenance bronchodilator
treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD),
including chronic bronchitis and emphysema.
PM: https://pdf.hres.ca/dpd_pm/00072581.PDF; date April 8, 2014; DIN 02423596; fetched 2026-09-10
Product monograph
UMECLIDINIUM & VILANTEROL · Limited Use, codes 459
1 INDICATIONS
ANORO ELLIPTA (umeclidinium/vilanterol) is a combination of a long-acting muscarinic antagonist
(LAMA) and a long-acting beta2-agonist (LABA) indicated for the long-term once-daily maintenance
bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease
(COPD), including chronic bronchitis and emphysema.
PM: https://pdf.hres.ca/dpd_pm/00069868.PDF; date March 14, 2014; DIN 02418401; fetched 2026-09-10
Product monograph
Coverage source: ON formulary extract 2026-08-26